KPTI
Closed
Karyopharm Therapeutics Inc
4.36
+0.05 (+1.16%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 4.31
Day's Range: 4.25 - 4.48
Send
sign up or login to leave a comment!
When Written:
4.1
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company that develops novel therapies for the treatment of cancer and other diseases. The company was founded in 2008 and is headquartered in Newton, Massachusetts.
Karyopharm's lead product candidate, selinexor, is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound that inhibits the export of tumor suppressor proteins from the nucleus of cancer cells. Selinexor is currently being evaluated in multiple clinical trials for the treatment of various hematologic and solid tumor malignancies.
In addition to selinexor, Karyopharm is also developing several other SINE compounds and other novel drug candidates that target nuclear transport and related pathways.
The company has collaborations with several pharmaceutical companies, including Biogen, Ono Pharmaceutical, and Anivive Lifesciences, to develop and commercialize its drug candidates.
As of 2021, Karyopharm has a market capitalization of approximately $1.4 billion and employs approximately 200 people.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Karyopharm's lead product candidate, selinexor, is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound that inhibits the export of tumor suppressor proteins from the nucleus of cancer cells. Selinexor is currently being evaluated in multiple clinical trials for the treatment of various hematologic and solid tumor malignancies.
In addition to selinexor, Karyopharm is also developing several other SINE compounds and other novel drug candidates that target nuclear transport and related pathways.
The company has collaborations with several pharmaceutical companies, including Biogen, Ono Pharmaceutical, and Anivive Lifesciences, to develop and commercialize its drug candidates.
As of 2021, Karyopharm has a market capitalization of approximately $1.4 billion and employs approximately 200 people.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!